CLAIMS

1. A use of a combination for the manufacture of a medicament for inhibiting uterine endometrial proliferation in a subject in need thereof, said combination comprising

i) a pharmaceutical composition suitable for oral administration wherein ulipristal acetate is orally administered in a therapeutically effective daily amount of 5 to 20 mg and

ii) a pharmaceutical composition suitable for vaginal and/or intrauterine administration wherein ulipristal acetate (CDB-2914)is released at an effective daily release amount of amount of 0.1 to 20 mg characterized in that said pharmaceutical composition suitable for oral administration and said pharmaceutical composition suitable for vaginal and/or intrauterine administration are co-administered, either concomitantly, or separately.

2. A use of a combination for the manufacture of a medicament for reducing uterine bleeding in a subject in need thereof, said combination comprising

i) a pharmaceutical composition suitable for oral administration wherein ulipristal acetate is orally administered in a therapeutically effective daily amount of 5 to 20 mg. comprising a therapeutically effective amount of a first progesterone receptor modulator, or any active metabolite thereof, and

ii) a pharmaceutical composition suitable for vaginal and/ or intrauterine administration wherein ulipristal acetate (CDB-2914) is released at an effective daily release amount of amount of 0.1 to 20 mg

characterized in that said pharmaceutical composition suitable for oral administration and said pharmaceutical composition suitable for vaginal and/ or intrauterine administration are co-administered, either concomitantly, or separately.

3. A use of a combination for the manufacture of a medicament for reducing myoma volume in a subject in need thereof, said combination comprising

i) a pharmaceutical composition suitable for oral administration wherein ulipristal acetate is orally administered in a therapeutically effective daily amount of 5 to 20 mg and

ii) a pharmaceutical composition suitable for vaginal and/or intrauterine administration wherein ulipristal acetate (CDB-2914) is released at an effective daily release amount of amount of 0.1 to 20 mg

characterized in that said pharmaceutical composition suitable for oral administration and said pharmaceutical composition suitable for vaginal and/ or intrauterine administration are co-administered, either concomitantly, or separately.